

Patents for beginners

– Why should you protect your oncology innovation?



INVITATION – June 18th, 2014 - Seminar room FOBY2, the Research Building, OUS Radiumhospitalet, Ullernchausseen 70, Oslo

Please register here before 16 June, 2014

For more information please contact Susanne Werner, **sw@oslocancercluster.no**. Due to limited space, Oslo Cancer Cluster members will have priority.

Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 kindly invite researchers, clinicians and start-ups to learn more about the patenting process. This breakfast seminar has a special focus on protecting innovations in oncology projects.

Welcome!

PROGRAM

09.50-10.00 ▶ Q&A

The seminar starts with breakfast from 08.00 am. The program starts at 08.30. Moderator: Sigrid Fossheim, Norwegian Cancer Society

08.00	▶ Breakfast and networking
08.30	Welcome and latest update from Oslo Cancer Cluster Incubator
	Ketil Widerberg, General Manager, Oslo Cancer Cluster
08.40	Why is it important to protect your oncology innovation?
	Bjørn Lillekjendlie, Director Patent department, Norwegian Industrial Property Office
09.00	▶ What can be patented, how to proceed and what is absolutely crucial in the process?
	Elen Margrethe Brendeford, Patent examiner, Norwegian Industrial Property Office
09.20	▶ Q&A
09.30	▶ How Inven2 work with securing IPR: strategies and challenges in the field of oncology.
	Kirsten Stangeby, IPR Manager and Mohammed Amarzguioui, Technology Strategy Manager,
	both at Inven2.





Patents for beginners

– Why should you protect your oncology innovation?

SPEAKERS:

- ▶ Bjørn Lillekjendlie has a technical education in ICT, Statistics and Physics. He has long experience from commercialization in technology-based start-up companies, as well as from licensing of patents. Lillekjendlie has both the researcher's and the management perspective from leading positions in companies like SINTEF, Onsagers and Oslotech. The last year he has led the patent department of the Norwegian Industrial Property Office.
- ▶ Elen Margrethe Brendeford has a Master and PhD degree in Biochemistry/ Molecular Biology, and for 5 years she worked as a researcher at UiO in the research group of Odd Stokke Gabrielsen. Since December 2006 she has worked as a patent examiner, examining patent applications in the field of Biotechnology.
- ▶ Kirsten Stangebye has been in Birkeland Innovasjon/Inven2 since 2007, and is responsible for the company's patent portfolio, including evaluating patentability of new ideas, protection of rights and IPR strategy in the projects. Before joining Inven2, she worked for several years as an examiner in the field of biotechnology at the Norwegian Industrial Property Office (Patentstyret). Kirsten has a master degree in Biochemistry from the University of Oslo.
- ▶ Mohammed Amarzguioui has a PhD in Molecular Biology, and did his postdoctoral training at an applied research lab in City of Hope, California. He became Research Director of the preclinical oncology company SiRNAsense A/S. As research director he was contributing to IPR management. In 2011 he joined Inven2 as Technology Strategy Manager. His portfolio has a particular focus on oncology therapy and diagnostics.

Coming Up – Oslo Cancer Cluster Incubator Meeting Series 2014

September – Biotech Start-ups: How to prepare for capital raising

November – Topic: to be announced